Full-Time

Senior Manager

Supply Chain, Logistics & Inventory

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$158k - $198k/yr

+ Equity Awards + Benefits + Learning and Development Opportunities

Senior, Expert

San Carlos, CA, USA

Hybrid

This position is hybrid, requiring some in-office presence at the headquarters in Redwood City, CA.

Category
Inventory Management
Transportation & Distribution
Operations & Logistics
Required Skills
Supply Chain Management
Inventory Management
Data Analysis
Requirements
  • B.Sc. or M.Sc. in Supply Chain Management, Engineering, Business, Accounting/Finance, or related field with 8+ years of experience in pharmaceutical logistics and inventory management.
  • Experience in Supply Chain processes is strongly preferred.
  • Experience in implementing and managing inventory management systems (i.e., ERP).
  • Experience in commercial product launch preparation and execution.
  • Experience in contract packaging and 3PL distribution operation.
  • Experience in developing, negotiating, and executing master service agreements.
  • Experience managing, analyzing, and communicating results to senior leadership.
  • Experience implementing repeatable processes and driving automation or standardization.
  • Experience defining program requirements and using data and metrics to determine improvements.
  • Experience managing both strategic and tactical/operational projects.
  • Working knowledge of GMP and GDP.
  • Working knowledge of end-to-end pharmaceutical supply chain and demand/supply planning.
  • Working knowledge of small molecule drug development and commercialization.
  • Working knowledge of pharmaceutical commercial manufacturing, regulatory, and quality assurance.
  • Working knowledge of customs regulations and international trade compliance.
  • Working knowledge of dangerous goods / hazardous material transportation regulations, classifications, packaging, and transit requirements e.g. IATA, DOT, hazmat.
  • Strong negotiation skills.
  • Solid project management, facilitation, and problem-solving skills.
  • Solid organizational and time management skills.
  • Strong communicator and connector between Commercial, Finance, Quality, Regulatory, and Supply Chain teams.
  • Effective, open, and transparent communication skills (verbal and written).
  • Capable of working on multiple projects/tasks and able to meet timelines.
  • Self-starter with a high level of comfort with ambiguity and complexity and the ability to multi-task while consistently delivering quality results.
  • A team-oriented progressive thinker who enjoys participating in an innovative and creative work environment.
Responsibilities
  • Serve as the subject matter expert for all logistics matters for RevMed.
  • Ensure all supplies are controlled and distributed in accordance with Good Manufacturing Practices (GMP), Good Clinical Practices (GCP), and Good Distribution Practices (GDP).
  • Manage global logistics and distribution of finished drug products and all intermediates.
  • Evaluate, select, onboard, and manage freight forwarders and warehousing depot services to support RevMed’s commercial supply chain.
  • Manage shipping validation to support NDA filing.
  • Develop, maintain, and enforce logistics management business processes and/or SOPs.
  • Ensure optimized and compliant transportation of goods.
  • Create and manage internal reports for key logistics costs such as storage costs, picking costs, freight costs, cargo insurance, VAT claims, and recollection.
  • Implement and manage an inventory management system to support commercial launch.
  • Ensure reconciliation of raw materials, work-in-progress (WIP), and finished goods inventory to comply with Sarbanes’s Oxley (SOX) standards.
  • Develop and implement strategies to maintain optimal inventory levels, balancing supply with production and sales demand.
  • Generate and analyze reports on inventory levels, usage, and forecasts, providing insights to management.
  • Establish and direct cycle count programs. Investigate discrepancies and root cause analysis.
  • Establish supply chain master data and establish a program to monitor and increase accuracy.
  • Develop, maintain, and enforce inventory management business processes and/or SOPs.
  • Identify and implement process improvements to increase efficiency, reduce costs, and minimize waste.
Desired Qualifications
  • American Production and Inventory Control Society (APICS) certification.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective, targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • $2 billion capital raise supports global expansion and commercialization strategies.
  • Acquisition of EQRx enhances market reach and competitive positioning.
  • Recognition for transformative pancreatic cancer research highlights leadership in oncology.

What critics are saying

  • EQRx acquisition may dilute focus on high-value cancer therapies.
  • Independent global strategy could strain resources and delay market entry.
  • $750 million debt facility increases financial risk if commercialization fails.

What makes Revolution Medicines unique

  • Revolution Medicines synthesizes pharmaceutically optimized analogues of complex natural products.
  • Their Tri Complex Inhibitor platform creates highly specialized cancer treatments.
  • Focus on RAS gene mutations addresses critical unmet medical needs in oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

8%
MarketScreener
Jun 24th, 2025
Revolution Medicines, Inc Announces Debt Facility Up to $750 Million Senior Secured Term Loan

Revolution Medicines, Inc. announced that the debt facility up to $750 million senior secured term loan consisting of three $250 million tranches linked to commercialization of daraxonrasib. The...

BioWorld
Jun 24th, 2025
Revmed secures $2B for global expansion

Revolution Medicines (Revmed) has secured $2 billion in capital to develop its own global commercial infrastructure for RAS(ON) inhibitors, targeting RAS-addicted cancers. The company decided to independently manage its global development and commercial strategies, rather than partnering outside the U.S. as initially planned, according to CEO Mark Goldsmith.

BioWorld
Jun 24th, 2025
Revmed goes global with $2B in capital for RAS(ON) inhibitors

Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial infrastructure, instead of partnering outside the U.S. as it had originally intended.

PRWeb
May 9th, 2025
The Lustgarten Foundation Honors Revolution Medicines For Transformative Research In Pancreatic Cancer

"Revolution Medicines exemplifies the power of bold science and collaboration in driving meaningful progress for patients," said Linda Tantawi, CEO of the Lustgarten Foundation

Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.